Berlin, Germany

Lars Stoeckl

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2016-2019

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Inventor Lars Stoeckl: Pioneering Advances in Antibody Production

Introduction: Lars Stoeckl, based in Berlin, Germany, is an innovative inventor contributing significantly to the field of biotechnology. With a commendable portfolio that includes two notable patents, Stoeckl's work focuses on enhancing antibody production techniques, specifically targeting glycosylation patterns that can improve therapeutic efficacy.

Latest Patents: Stoeckl's most recent patents include:

1. **Use of human cells of myeloid leukemia origin for expression of antibodies** - This invention relates to a method for producing a protein molecule composition with a specific glycosylation pattern. The process involves introducing nucleic acids encoding parts of the protein into immortalized human blood cells, culturing these cells, and isolating the resultant protein molecule composition.

2. **Fab-glycosylated antibodies** - This patent introduces a method for controlling the circulation half-life of antibodies by adjusting the sialic acid amounts in the carbohydrates linked to the Fab region. It also encompasses antibodies designed to have an increased circulation half-life, improving their therapeutic applicability.

Career Highlights: Lars Stoeckl's career is marked by his impactful contributions at Glycotope GmbH, where he has played a key role in advancing innovative biotechnological solutions. His expertise and inventive spirit have positioned him as a valuable asset in the research and development of new antibody production methods.

Collaborations: Throughout his professional journey, Stoeckl has collaborated with notable peers, including Steffen Goletz and Antje Danielczyk. Their teamwork fosters a creative synergy that continues to drive innovation within the company and the broader biotechnology sector.

Conclusion: Lars Stoeckl stands out as a visionary inventor in the biotechnology field, with a focus on optimizing antibody production processes. His patents not only enhance the understanding of glycosylation in antibodies but also pave the way for developing more effective therapeutic options. As he continues to work with Glycotope GmbH and collaborate with talented colleagues, the future of antibody technology looks promising.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…